Oncology Drugs - Egypt | Statista Market Forecast

The market of Oncology Drugs market in Egypt is anticipated to witness a remarkable growth in revenue, with a projected value of US$217.50m in 2024.
Furthermore, it is expected to display a steady annual growth rate (CAGR 2024-2029) of 8.70%, leading to a substantial market volume of US$330.20m by 2029.
In a global context, it is worth noting that United States is projected to generate the highest revenue in this market, estimated at US$103.90bn in 2024.
Egypt's oncology drug market is experiencing a surge in demand due to the increasing prevalence of cancer cases in the country.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
Chemotherapeutic agents
Immuno-oncology drugs
Oncology orphan drugs

Radiation therapy
Medical devices

The demand for Oncology Drugs in Egypt has been on a steady rise in recent years.

Customer preferences: The majority of the Egyptian population relies on public healthcare, which has limited resources for cancer treatment. This has created a gap in the market, which private healthcare providers have been filling. As a result, the demand for Oncology Drugs has increased, as they are the primary treatment for cancer.

Trends in the market: One of the key trends in the Oncology Drugs market in Egypt is the increasing prevalence of cancer. The country has a high incidence of cancer, with breast cancer being the most common type among women. This has led to an increase in the demand for Oncology Drugs, as they are the primary treatment for cancer.Another trend in the market is the increasing number of pharmaceutical companies entering the market. This has led to increased competition, which has resulted in lower prices for Oncology Drugs. This has made them more affordable for patients, which has further increased demand.

Local special circumstances: One of the key special circumstances in the Oncology Drugs market in Egypt is the limited resources available for cancer treatment in public healthcare. This has created a gap in the market, which private healthcare providers have been filling. As a result, the demand for Oncology Drugs has increased.Another special circumstance is the high incidence of cancer in the country. This has led to an increase in the demand for Oncology Drugs, as they are the primary treatment for cancer.

Underlying macroeconomic factors: One of the key macroeconomic factors driving the Oncology Drugs market in Egypt is the increasing population. With a growing population, the number of cancer cases is also increasing, which has led to an increase in the demand for Oncology Drugs.Another macroeconomic factor is the increasing income levels in the country. As income levels rise, more people are able to afford private healthcare, which has further increased demand for Oncology Drugs.In conclusion, the Oncology Drugs market in Egypt is on a steady rise, driven by the increasing prevalence of cancer, the limited resources available for cancer treatment in public healthcare, the increasing number of pharmaceutical companies entering the market, and the increasing population and income levels in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.